What does the KRAS protein do?

What does the KRAS protein do?

The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell’s nucleus.

What is KRAS G12 mutation?

The small GTPase protein KRAS is a signal-transducing protein, which binds GDP in its inactive state and GTP in its active state [1]. The gene KRAS is frequently mutated in various human cancers. The mutation is most often, in about 86% of the cases [2], found at G12.

What does KRAS-positive mean?

KRAS-positive lung cancer, refers to any lung cancer that tests positive for a KRAS biomarker. The KRAS biomarker is present in approximately 15-25% of patients with non-small cell lung cancer (NSCLC). The KRAS biomarker belongs to a class of genes known as oncogenes.

Can KRAS mutation be cured?

KRAS mutations are the most common oncogenic alteration in all of human cancers and there are currently no effective treatments available for patients with KRAS-mutant cancers.

Is KRAS mutation bad?

In CRC, the presence of KRAS mutation is associated with increased metastatic potential and lack of treatment benefit from anti-EGFR monoclonal antibody therapy7,8. CRC patients with KRAS-mutant tumors have worse overall survival (OS) and increased incidence of lung, bone and brain metastasis9,10,11.

How to compare KRAS siRNAs to other products?

Select 2-6 products that you want to compare. To select a product, click the box next to the Product ID Please confirm your Size & Purification selections before adding to your cart. Please confirm your Size & Purification selections before adding to your cart.

How is siRNA used to treat pancreatic cancer?

Purpose: The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months. This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC).

Are there any RNAi therapies that target KRAS?

DOI: 10.18632/oncotarget.4183 Abstract Purpose: The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months.